Product Name :
25-Desacetyl Rifampicin (CAS 16783-99-6)
Synonym :
25-O-Deacetyl-3-[(E)-[(4-methyl-1-piperazinyl)imino]methyl]rifamycin; 25-Deacetylrifampicin
Application :
25-Desacetyl Rifampicin is a metabolite of Rifampicin
CAS:
16783-99-6
Purity:
≥96%
Molecular Weight:
780.90
Formula :
C41H56N4O11
Physical state:
Solid
solubility :
Soluble in methanol.
Shipping Condition :
Store at -20° C
Melting point:
>300° C
SMILES:
C[C@H]1/C=C/C=C(\\C(=O)NC\\2=C(C3=C(C(=C4C(=C3C(=O)/C2=C/NN5CCN(CC5)C)C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)O)C)OC)C)C)O)O)/C
References:
:Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption. | Ellard, GA. and Fourie, PB. 1999. Int J Tuberc Lung Dis. 3: S301-8; discussion S317-21. PMID: 10593709The WHO simplified study protocol in practice: investigation of combined formulations supplied by the WHO. | Panchagnula, R., et al. 1999. Int J Tuberc Lung Dis. 3: S336-42; discussion S351-2. PMID: 10593714Evaluation of the recently reported USP gradient HPLC method for analysis of anti-tuberculosis drugs for its ability to resolve degradation products of rifampicin.Metformin web | Mohan, B.3-Amino-6-chloropyridazine supplier , et al. 2003. J Pharm Biomed Anal. 31: 607-12. PMID: 12615251Mechanistic explanation to the catalysis by pyrazinamide and ethambutol of reaction between rifampicin and isoniazid in anti-TB FDCs. | Bhutani, H., et al. 2005. J Pharm Biomed Anal. 39: 892-9. PMID: 15978767Control and analysis of hydrazine, hydrazides and hydrazones–genotoxic impurities in active pharmaceutical ingredients (APIs) and drug products. | Elder, DP., et al. 2011. J Pharm Biomed Anal.PMID:33638882 54: 900-10. PMID: 21145684A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers. | Chik, Z., et al. 2010. Clin Ther. 32: 1822-31. PMID: 21194606Fatal poisoning by isoniazid and rifampicin. | Sridhar, A., et al. 2012. Indian J Nephrol. 22: 385-7. PMID: 23326053Troubleshooting carry-over of LC-MS/MS method for rifampicin, clarithromycin and metabolites in human plasma. | Vu, DH., et al. 2013. J Chromatogr B Analyt Technol Biomed Life Sci. 917-918: 1-4. PMID: 23353809Relationship between CES2 genetic variations and rifampicin metabolism. | Song, SH., et al. 2013. J Antimicrob Chemother. 68: 1281-4. PMID: 23471941Aggregate culture of human embryonic stem cell-derived hepatocytes in suspension are an improved in vitro model for drug metabolism and toxicity testing. | Sengupta, S., et al. 2014. Toxicol Sci. 140: 236-45. PMID: 24752503Population Pharmacokinetic Analysis of Rifampicin in Plasma, Cerebrospinal Fluid, and Brain Extracellular Fluid in South African Children with Tuberculous Meningitis. | Abdelgawad, N., et al. 2023. Antimicrob Agents Chemother. 67: e0147422. PMID: 36815838In vitro effect of rifampicin and its derivatives on energy transfer reactions in mitochondria. | Inouye, B., et al. 1974. J Antibiot (Tokyo). 27: 192-8. PMID: 4275810Determination of rifampicin and its main metabolite in plasma and urine in presence of pyrazinamide and isoniazid by HPLC method. | Panchagnula, R., et al. 1999. J Pharm Biomed Anal. 18: 1013-20. PMID: 9925337